Dimensional Fund Advisors LP Raises Stake in Hologic, Inc. (NASDAQ:HOLX)

Dimensional Fund Advisors LP raised its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 5.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,326,992 shares of the medical equipment provider’s stock after buying an additional 124,739 shares during the quarter. Dimensional Fund Advisors LP owned about 1.00% of Hologic worth $172,780,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Cetera Investment Advisers grew its stake in Hologic by 188.9% during the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after acquiring an additional 13,380 shares in the last quarter. Nordea Investment Management AB grew its position in shares of Hologic by 1.3% during the 1st quarter. Nordea Investment Management AB now owns 1,507,743 shares of the medical equipment provider’s stock valued at $116,797,000 after purchasing an additional 19,680 shares in the last quarter. Pinebridge Investments L.P. increased its holdings in shares of Hologic by 39.8% in the fourth quarter. Pinebridge Investments L.P. now owns 397,251 shares of the medical equipment provider’s stock worth $28,384,000 after purchasing an additional 113,050 shares during the period. Clearbridge Investments LLC raised its position in shares of Hologic by 51.4% in the first quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock worth $40,430,000 after buying an additional 176,006 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Hologic by 18.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,184,427 shares of the medical equipment provider’s stock worth $170,297,000 after buying an additional 338,212 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

HOLX has been the subject of several recent analyst reports. StockNews.com cut Hologic from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday. Stephens reaffirmed an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Royal Bank of Canada reiterated a “sector perform” rating and set a $82.00 target price on shares of Hologic in a research report on Friday, August 16th. Finally, Evercore ISI increased their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $87.60.

Insider Buying and Selling at Hologic

In other news, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the transaction, the insider now owns 3,735 shares in the company, valued at $310,415.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Hologic news, insider Brandon Schnittker sold 476 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is currently owned by insiders.

Hologic Price Performance

HOLX stock opened at $81.39 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The firm has a market cap of $18.99 billion, a P/E ratio of 41.53, a P/E/G ratio of 2.53 and a beta of 0.98. The firm’s fifty day moving average is $80.74 and its 200 day moving average is $77.05. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.93 earnings per share. Research analysts predict that Hologic, Inc. will post 4.09 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.